Abstract | OBJECTIVE: STUDY DESIGN: This was a randomized, double-blind, 41-site study in 194 children aged 10 to 17 years (inclusive) with heFH ( statin-naïve or on a stable statin regimen). After a 4-week stabilization period (period I), subjects were randomized 1:1:1 to placebo, colesevelam 1.875 g/d, or colesevelam 3.75 g/d for 8 weeks (period II). All then received open-label colesevelam 3.75 g/d for 18 weeks (period III), with follow-up 2 weeks later. The primary endpoint was percent change in low-density lipoprotein ( LDL)-cholesterol from baseline to week 8. Secondary endpoints included percent change in other lipoprotein variables, including non- high-density lipoprotein (non- HDL)-cholesterol. Adverse events were also evaluated. RESULTS: CONCLUSIONS:
|
Authors | Evan A Stein, A David Marais, Tamas Szamosi, Frederick J Raal, Daniel Schurr, Elaine M Urbina, Paul N Hopkins, Sulekha Karki, Jianbo Xu, Soamnauth Misir, Michael Melino |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 156
Issue 2
Pg. 231-6.e1-3
(Feb 2010)
ISSN: 1097-6833 [Electronic] United States |
PMID | 19879596
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2010 Mosby, Inc. All rights reserved. |
Chemical References |
- Anticholesteremic Agents
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Allylamine
- Colesevelam Hydrochloride
|
Topics |
- Adolescent
- Allylamine
(adverse effects, analogs & derivatives, pharmacology, therapeutic use)
- Anticholesteremic Agents
(adverse effects, pharmacology, therapeutic use)
- Child
- Cholesterol, LDL
(blood, drug effects)
- Colesevelam Hydrochloride
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Drug-Related Side Effects and Adverse Reactions
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage)
- Hyperlipoproteinemia Type II
(drug therapy)
- Male
|